NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of “Buy” from Brokerages
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year […]
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) has received an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued a report on the stock in the last year […]